Outlook Therapeutics Q3 net loss narrows slightly as costs drop

Outlook Therapeutics

14/08/2026 12:26

Overview
U.S. biopharmaceutical firm's fiscal Q3 net loss narrowed
Company advancing U.S. launch strategy for LYTENAVA, FDA-approved ophthalmic bevacizumab for wet AMD
Company raised $51.1 mln in net proceeds from public offering after quarter end

Outlook
Outlook Therapeutics plans U.S. LYTENAVA launch by end of calendar 2026
Company estimates LYTENAVA annual U.S. sales could exceed $500 mln by 2030
Company to submit for permanent HCPCS code by Oct. 1, 2026, to support reimbursement

Result Drivers
LOWER OPERATING EXPENSES - Operating expenses declined from prior year, mainly due to reduced research and development and selling, general and administrative costs
EUROPEAN COMMERCIALIZATION - Co continued to expand commercialization of LYTENAVA in Germany, Austria, and the UK, with further launches planned in Europe

Company press release: ID:nGNX15ThPB

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Loss Per Share
 
$0.15
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Outlook Therapeutics Inc is $5.00, about 462.6% above its August 13 closing price of $0.89

Reuters Recommended Reads
Aug 11 - LENZ Therapeutics Q2 revenue rises on VIZZ sales
Aug 13 - Kodiak Sciences Q2 net loss widens on higher R&D costs
Aug 11 - Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)